Physical Activity Monitoring for Brain Cancer
Recruiting in Palo Alto (17 mi)
Overseen byShiao-Pei S Weathers
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: M.D. Anderson Cancer Center
Disqualifiers: Cognitive deficits, Major sensory deficits
No Placebo Group
Trial Summary
What is the purpose of this trial?This trial studies the feasibility of monitoring step count as a measure of physical activity in patients with newly diagnosed glioma undergoing radiation therapy. Physical activity measured by step count may help to improve the quality of life and symptoms for patients with newly diagnosed glioma.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It focuses on monitoring physical activity in patients with brain cancer.
What data supports the effectiveness of the treatment Step Count Monitoring for brain cancer?
Research shows that increasing physical activity, like monitoring step counts, is safe and beneficial for lung cancer patients, improving their quality of life. This suggests that similar benefits might be seen in brain cancer patients using step count monitoring.
12345Is physical activity monitoring safe for people with brain cancer?
Research, such as the BRACE study, has looked into the safety of exercise interventions for adults with primary brain cancer, suggesting that monitoring physical activity is generally safe for humans.
13678How does physical activity monitoring differ from other treatments for brain cancer?
Physical activity monitoring for brain cancer is unique because it uses wearable devices to track real-time physical activity, providing continuous and objective data. This approach differs from traditional treatments as it focuses on monitoring physical function and recovery, rather than directly treating the cancer itself.
14678Eligibility Criteria
This trial is for English-speaking patients with a new glioma diagnosis who are starting at least 4 weeks of radiation therapy. Participants must have a good performance status, meaning they can carry out daily activities without significant help, be able to consent, own a smartphone, have Wi-Fi access, and not already use wearable activity trackers.Inclusion Criteria
I have a glioma and will undergo radiation therapy for at least 4 weeks.
Able to provide informed consent
You need to have Wi-Fi available.
+4 more
Exclusion Criteria
Cognitive and/or major sensory deficits that would impede the completion of assessment instruments as deemed by the clinical team
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Radiation Therapy
Patients undergo radiation therapy while their physical activity is monitored using either a pedometer or a FitBit
6 weeks
Weekly visits for radiation therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
6 months
Follow-up visits at 3 and 6 months
Participant Groups
The study is testing if using devices like FitBits or pedometers to monitor steps can help understand physical activity levels in patients undergoing radiation therapy for brain tumors. It aims to see if tracking steps could improve life quality and manage symptoms during treatment.
2Treatment groups
Experimental Treatment
Active Control
Group I: Group II (FitBit)Experimental Treatment3 Interventions
Patients wear a FitBit for step count monitoring over 6 weeks.
Group II: Group I (pedometer)Active Control3 Interventions
Patients wear a pedometer for step count monitoring over 6 weeks.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
M D Anderson Cancer CenterHouston, TX
Loading ...
Who Is Running the Clinical Trial?
M.D. Anderson Cancer CenterLead Sponsor
National Cancer Institute (NCI)Collaborator
References
Daily Step Counts: A New Prognostic Factor in Locally Advanced Non-Small Cell Lung Cancer? [2020]Here we explore the prognostic value of baseline step count data captured using wearable devices for patients treated with definitive chemoradiation therapy for locally advanced non-small cell lung cancer (NSCLC).
Assessing the Correlation Between Physical Activity and Quality of Life in Advanced Lung Cancer. [2018]Increasing physical activity (PA) is safe and beneficial in lung cancer (LC) patients. Advanced-stage LC patients are under-studied and have worse symptoms and quality of life (QoL). We evaluated the feasibility of monitoring step count in advanced LC as well as potential correlations between PA and QoL.
The safety, feasibility, and efficacy of an 18-week exercise intervention for adults with primary brain cancer - the BRACE study. [2023]To determine the safety, feasibility, and potential effect of an 18-week exercise intervention for adults with primary brain cancer.
A guide to assessing physical activity using accelerometry in cancer patients. [2021]Increased physical activity (PA) has been associated with a decreased risk for the occurrence and recurrence of many cancers. PA is an important outcome measure in rehabilitation interventions within cancer and may be used as a proxy measure of recovery or deterioration in health status following treatment and in the palliative care setting. PA is a complex multi-dimensional construct which is challenging to measure accurately. Factors such as technical precision and feasibility influence the choice of PA measurement tool. Laboratory-based methods are precise and mainly used for validation purposes, but their clinical applicability is limited. Self-report methods such as questionnaires are widely used due to their simplicity and reasonable cost; however, accuracy can be questionable. Objective methods such as pedometers measure step count but do not measure intensity, frequency or duration of activity. Accelerometers can measure PA behaviour at both ends of the movement spectrum from sedentary to vigorous levels of activity and can also provide objective data about the frequency, intensity, type and duration of PA. Balancing precision with ease of use, accelerometry may be the best measure of PA in cancer-based studies, but only a small number of studies have incorporated this measurement. This review will provide a background to PA and an overview of accelerometer measurement as well as technical and practical considerations, so this useful tool could be more widely incorporated into clinical trial research within cancer.
Assessment of gait parameters and physical function in patients with advanced cancer participating in a 12-week exercise and nutrition programme: A controlled clinical trial. [2021]Gait is a sensitive marker for functional declines commonly seen in patients treated for advanced cancer. We tested the effect of a combined exercise and nutrition programme on gait parameters of advanced-stage cancer patients using a novel wearable gait analysis system.
Triaxial accelerometer-measured physical activity and functional behaviours among people with High Grade Glioma: The BrainWear Study. [2023]High-grade gliomas (HGG) account for 60-75% of all adult gliomas. The complexity of treatment, recovery and survivorship creates a need for novel monitoring approaches. Accurate assessment of physical function plays a vital role in clinical evaluation. Digital wearable tools could help us address unmet needs by offering unique advantages such as scale, cost and continuous real-world objective data. We present data from 42 patients enrolled into the BrainWear study.
Daily physical activity monitoring in older adults with metastatic prostate cancer on active treatment: Feasibility and associations with toxicity. [2023]Physical activity may be associated with cancer treatment toxicity, but generalizability to geriatric oncology is unclear. As many older adults have low levels of physical activity and technology use, this area needs further exploration. We evaluated the feasibility of daily step count monitoring and the association between step counts and treatment-emergent symptoms.
Wearable activity monitors in oncology trials: Current use of an emerging technology. [2019]Physical activity is an important outcome in oncology trials. Physical activity is commonly assessed using self-reported questionnaires, which are limited by recall and response biases. Recent advancements in wearable technology have provided oncologists with new opportunities to obtain real-time, objective physical activity data. The purpose of this review was to describe current uses of wearable activity monitors in oncology trials.